

ACURIAN CASE STUDY:

Predictable, reliable, and
measurable results



Acurian Delivers 32% of US Patient Randomizations to an Asthma Program

Respiratory disease is a core therapeutic area for this sponsor. When it announced the start of its Phase III program for its compound as a potential treatment for severe uncontrolled asthma, the sponsor was facing a crowded field. There were four other products in Phase III and multiple products in Phase II. Because this class of drug was in a race to approval, keeping the program on track and filing a BLA as quickly as possible were paramount.


Sites faced significant enrollment challenges caused by a difficult protocol.

To qualify, patients must have had two or more exacerbations in the past year; a high dose of inhaled corticosteroids was required; the study duration was long; and the drug was an injectable form. As a result, enrollment faltered, and a significant delay was projected – a major delay that was unacceptable in such a tight race to market.

The clinical trial team needed a reliable solution to close the gap, so they hired Acurian to support two protocols across US sites.

Acurian delivered 32% (120) of all US randomizations, over the time of its engagement.

Contribution of US Patient
Randomizations



■ Acurian Patients
■ In-practice Patients

(continued on other side)

